Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human...

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Malignant progression can increase cancer cell sensitivity to viruses, supporting oncolytic virus therapy.
• Understanding molecular changes in virus sensitivity aids in selecting effective oncolytic virus treatments.

Purpose of the Study:

• To quantify protein abundance changes in glioblastoma cell lines with differing resistance to vesicular stomatitis virus (VSV) after type I interferon (IFN) treatment.
• To investigate molecular mechanisms underlying altered virus sensitivity in glioblastoma.

Main Methods:

• Proteome analysis of two glioblastoma multiforme cell lines (one VSV-sensitive, one resistant) after IFN treatment.
• Protein-protein interaction and signaling pathway analyses.
• Quantification of IFN-regulated gene (IRG) protein products.

Main Results:

• IFN treatment upregulated IRG proteins in both cell lines.
• The VSV-resistant cell line showed a 20% increase in IRG proteins compared to the sensitive line.
• Signaling pathway analysis revealed enhanced type I IFN signaling and antiviral responses in both cell lines.
• A STAT2 protein deficiency was observed in the VSV-sensitive cell line, indicating JAK/STAT/IRF9 pathway dysregulation.

Conclusions:

• IFNα treatment induces detectable proteomic changes in glioblastoma cells, including IRG protein upregulation.
• Proteome analysis can reveal functional alterations in antiviral mechanisms and predict oncolytic virus sensitivity in glioblastoma.
• Identifying biomarkers for oncolytic virus sensitivity is crucial for personalized glioblastoma therapy.